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The Council of the South African Menopause Society (SAMS) 
revised the 2004 statement1 on menopausal hormone therapy 
(HT) at a consensus meeting held on 25/26 November 2006. 
The revision incorporated not only new evidence but also the 
re-evaluated evidence used in the previous statement. 
Clinicians are expected to practise in accordance with the 
findings of evidence-based medicine. This implies that the 
clinician is familiar with the strongest evidence available. The 
latter is difficult for the following reasons: 
•  The results of a given clinical trial can only be applied to 
the specific population and circumstances as applicable to 
the study in question.
•  A small group of individuals may react in a unique way to 
medication.
•  Statistical significance does not always equate to clinical 
significance.
•  Different methods of defining statistical significance may 
yield different answers when applied to the same data.
•  Publications often only quote relative risks and ignore the 
clinically more relevant absolute risks.
•  The perception of the patient is always relevant – for 
example, a weak association between postmenopausal HT 
and breast cancer may be more important to women and 
the lay press than a possibly stronger association between 
HT and thrombo-embolic disease.
•  The side-effects of preventive medicine in healthy 
individuals have to be viewed differently from the side-
effects resulting from treatment for disease.
•  New results are being published at an increasingly rapid 
rate and this may complicate choices regarding treatment 
options.
•  For many years HT use was based on the results of 
observational trials; however, the results of large 
randomised trials are now also available.
•  Cancer, metabolic diseases, vascular disorders and brain 
ageing are not only the concerns of women on HT, but are 
of universal concern to women past reproductive age.
Clinical guidelines will not be able to cater for all situations, 
as there are still major gaps in our present knowledge. The 
final decision must be a joint decision between the health 
care provider and an informed patient, based on the relevant 
current clinical factors and ongoing new scientific evidence.
Estrogen alone will be referred to as ET and estrogen in 
combination with a progestogen as EPT. The term hormone 
therapy (HT) refers to either ET or EPT.
Position statement on present 
knowledge regarding menopausal HT
Systemic HT improves vasomotor symptoms and 
associated sleep disorders of early menopause 
HT remains the only treatment that has consistently had a 
greater effect than placebo in published controlled trials. It has 
been found that after 5 years the incidence of hot flushes is low 
in untreated patients, but follow-up of women who stopped 
EPT in the Women’s Health Initiative (WHI) trial showed that 
55.5% of women suffering from vasomotor symptoms at the 
start of the study, relapsed after cessation of treatment.2 ET is 
effective even in low dosages and the effect is enhanced by 
the addition of a progestogen. EPT did not improve quality of 
life (QOL) in mostly asymptomatic menopausal women in the 
WHI trial,3 but this may be a result of the specific instrument 
used to measure QOL. It is recommended that in clinical 
practice the individual patient herself judge the effect on QOL. 
Systemic or local HT is effective in the prevention 
and treatment of vulval and vaginal atrophy  
In cases of severe atrophy, initial combination of systemic 
and local therapy may be followed by local therapy alone. 
When correctly used, local estrogen preparations generally 
do not result in sufficient systemic absorption to warrant the 
use of progestogen for endometrial protection. The use of 
conjugated equine estrogen vaginal cream appears more likely 
to predispose to endometrial proliferation. At present there is 
not enough evidence to mandate progestogen use in women 
who persist with any local intra-vaginal estrogen preparations 
beyond 6 months. 
HT is effective in preventing bone loss associated 
with menopause
The increased rate of bone resorption immediately after 
menopause clearly indicates a hormonal influence on bone 
density in women.
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HT is effective in decreasing the incidence of all 
osteoporosis-related fractures, including vertebral and hip 
fractures, even in patients at low risk for fractures.
 The protective effect of HT on bone mineral density is lost 
at an unpredictable rate after cessation of therapy. Although 
some degree of fracture protection may remain after cessation 
of HT, the patient at risk for fracture should receive additional 
therapy with proven bone-sparing medication.4
EPT is associated with a small increase in the risk of 
invasive breast cancer, if used for more than 5 years 
Although the relative risk (RR) is in the order of 1.35, the 
absolute increase in risk is small (e.g. in the WHI study the risk 
was found to be 8/10 000 per year or less than 0.1% per year), 
but this increases with the duration of treatment if initiated 
after age of 50 years. It is possible that this does not imply 
causality, but rather modification of pre-existing malignancy. 
Carcinoma in situ has not been shown to increase. As the 
biological behaviour of breast cancer has not been adequately 
studied, firm conclusions cannot be drawn. The effect of 
EPT is more pronounced in lean patients. The increased risk 
disappears 5 years after cessation of therapy.
ET does not increase the risk of breast cancer
The increased risk of breast cancer shown with EPT is 
associated with the addition of progestogen and is absent when 
estrogen is used alone. The initial report on the estrogen-only 
arm of the WHI concluded that there was a non-significant  
(p < 0.06) decreased risk for breast cancer in ET users, but 
subgroup analyses now reveal that first lifetime exposure to ET 
at the trial was associated with significantly fewer breast cancer 
cases when compared with placebo (hazard ratio (HR) 0.76, 
95% confidence interval (CI): 0.58 - 0.99; p < 0.05). Women who 
took ET had significantly fewer breast cancers with localised 
disease and significantly fewer breast cancers with ductal 
carcinoma (HR 0.71, 95% CI: 0.52 - 0.99). Furthermore, women 
who were adherent to study medications had significantly 
fewer invasive breast cancers (HR 0.67, 95% CI: 0.47 - 0.97).5 
Having no first-degree relatives with breast cancer or personal 
history of benign breast disease was also associated with 
significantly fewer breast cancers in the ET users compared 
with the control group.
HT in standard doses increases breast density
This may lead to more breast biopsies and it may therefore be 
advisable to stop HT 2 - 4 weeks before mammography.
EPT reduces the risk of colorectal cancer
In the EPT arm of the WHI the overall incidence of newly 
diagnosed malignancies was equal in the treated and 
untreated groups, as the increase in breast cancer was offset 
by the reduction in incidence of colorectal and uterine cancer. 
Likewise, the all-cause mortality figure was the same in both 
groups. The reduction in risk of colorectal cancer was not 
shown in the ET arm of the WHI.
HT does not offer secondary protection against 
coronary heart disease (CHD) 
The WHI study failed in the primary endpoint to demonstrate 
a reduced risk of CHD in HT users. In the EPT arm, a 
significant increase in non-fatal CHD was found only in the 
first year, with a significant downward trend thereafter in 
women started on HT more than 10 years after the start of 
menopause (absolute risk 7/10 000 women per year). It can be 
speculated that an inappropriate population was used in the 
study considering their age, time since menopause and other 
risk factors for CHD.
HT may offer primary protection against CHD if 
started soon after menopause
The concept of an early window of opportunity is based on 
the assumption that estrogen offers protection only when 
the arterial endothelium is still intact and is supported by 
epidemiological studies, animal models and the ET arm of 
the WHI.6 There was an insignificant increase in CHD events, 
only in women older than 70 years at the beginning of the 
study, and in those who had been menopausal for at least 20 
years. However, in the younger women  (50 - 59 years) there 
were fewer CHD events in the hormone users compared 
with women in the placebo arm, although the data were not 
statistically significant because of a relatively small sample size 
and the low incidence of CHD in this age group. 
Additional evidence comes from the most recent analysis 
of the Nurses’ Health Study. With large subjects numbers the 
study was able to demonstrate that women starting HT near 
the menopause had a significantly reduced risk of CHD on 
ET (RR 0.66, 95% CI: 0.54 - 0.80) and on EPT (RR 0.72, 95% CI: 
0.56 - 0.92).7 Also, in a subgroup of women demographically 
similar to those in the WHI, there was no significant relation 
between HT and CHD among women who initiated therapy at 
least 10 years after the menopause using ET (RR 0.87, 95% CI: 
0.69 - 1.10) or on EPT (RR 0.90, 95% CI: 0.62 - 1.29).
There is not enough evidence to support any firm 
conclusion regarding the effect of HT on stroke
The WHI study reported an increased risk of thrombotic stroke 
(HR 1.39).  This is consistent with results from the Nurses 
Health Study. In contrast to venous thromboembolism (VTE), 
the effect was not confined to the first year, but was maintained 
throughout the study. However, the Danish Nurses Study8 
found that in 13 122 healthy postmenopausal women followed 
for 5 years, unopposed estradiol 1 mg daily was not associated 
with an increased risk of stroke (HR 0.80 (CI: 0.40 - 1.61). It is 
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possible that the effect of HT on stroke is dose related. Smaller 
doses may be protective and larger doses harmful.9
HT is not indicated for the treatment of Alzheimer’s 
disease
Early commencement of HT will have no detrimental effect 
and could possibly be beneficial in certain domains of cognitive 
performance. However, commencement of HT after 65 years of 
age may have detrimental effects.
HT increases the risk of VTE 
The relative risk of VTE is doubled with HT, but the absolute 
risk of VTE is increased by only 22 cases per 10 000 women per 
year. The effect is maximal in the first year of treatment and 
more pronounced with advancing age, obesity, previous VTE 
and underlying thrombophilia. The risk of VTE in the 50 - 60-
year age group is very small, but increases 4-fold in the 60 - 69-
year and 7-fold in the 70 - 79-year-old age groups. The route of 
delivery will impact on risk, with the highest risk being with 
EPT orally, then ET orally and least risk with the transdermal 
route. 
ET increases the risk of endometrial cancer 
The risk is significantly reduced with the addition of 
progestogen. The primary indication for progestogen use in 
women on HT is for endometrial protection and it should not 
be used in women who have had a hysterectomy.
HT should be offered to patients with premature 
menopause
Although this issue has not been addressed directly in recent 
studies, patients should be offered HT or low-dose combined 
hormonal contraception until at least the expected age of 
normal menopause (approximately 51 years).
Clinical guidelines regarding 
menopausal HT 
The menopausal transition should be utilised as a window of 
opportunity to assess and manage specific, as well as general, 
health-related matters. Medical history and examination 
should be supplemented with special investigations. These 
may include a fasting lipogram, blood glucose, mammography, 
thyroid function test and bone densitometry. Investigations for 
hypercoagulability states should only be undertaken in patients 
at risk (personal or family history of VTE) before instituting 
HT.
Lifestyle modifications such as the cessation of smoking, a 
healthy diet, and the maintenance of appropriate body mass 
index, exercise and stress reduction should be discussed. 
Treatment of dyslipidaemias, hypertension, diabetes and other 
medical conditions should be optimal.
HT should only be initiated for specific proven indications, 
provided there are no contraindications, and should be 
individualised according to each patient’s needs.
Indications
1. Treatment of vasomotor symptoms and associated sleep 
disorders.
2. Symptomatic urogenital atrophy.
3. Prevention of bone loss in women with premature 
menopause, secondary amenorrhoea and women with 
osteopenia at risk for fracture. 
4. The treatment of osteoporosis in women in the 50 - 60-
year age group at risk of fracture, with or without vasomotor 
symptoms. If HT is considered for the sole purpose of the 
prevention or treatment of osteoporosis, then other proven 
bone-specific therapies should be considered.
Contraindications
HT should generally not be prescribed where there is: 
• current, past or suspected breast cancer 
•  known or suspected estrogen-dependent malignant 
tumours 
• undiagnosed genital bleeding
• untreated endometrial hyperplasia
• previous idiopathic or current VTE 
• known arterial CHD
• active liver disease, or 
• porphyria cutanea tarda (absolute contraindication).
General guidelines
1. The duration of HT should be based on the indication for 
treatment.
2. The indication for therapy should be reviewed on an 
annual basis. The decision to determine whether to continue 
treatment for the relief of climacteric symptoms may be made 
by temporarily discontinuing treatment. If symptoms do 
not recur, HT does not have to be resumed. Topical therapy 
for relief of urogenital atrophy symptoms may need to be 
continued long term. Only long-term therapy is effective for 
the prevention or treatment of osteoporosis. Long-term HT can 
still be considered for bone effects, weighing its benefit and 
risks against those of alternative therapies. At present there 
is no compelling evidence to restrict duration of treatment as 
long as treatment goals are maintained. 
3. Systemic HT should in general not be initiated after the 
age of 60 years.
4. Until further evidence is available all estrogens and 
progestogen formulations, including tibolone, should be 
considered similar in terms of clinical risks and benefits.
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5. These statements are applicable to all routes of 
administration including transdermal application. The non-
oral route avoids the first-pass effect on the liver and may be 
preferable in conditions of hypertriglyceridaemia, liver disease, 
migraine, glucose intolerance and increased risk of VTE and in 
smokers.  
6. Should EPT be required for more than 5 years, it is 
recommended to convert from sequential HT to continuous 
combined HT. 
7. Low-dose therapy has been shown to be effective in 
symptom control and the prevention of bone loss; therefore the 
principle of lowest effective dose should be adhered to.  
8. It is recommended that before commencing HT, all 
patients should be advised to undergo breast screening, 
including mammography. Ideally, all menopausal women 
should have regular mammography.
9. Studies on phyto-estrogens and botanicals have shown 
inconsistent results. Most good studies show no clear benefit 
and some potential for harm. Further research is required in 
order to make firm recommendations. Patients should be made 
aware of this.
10. Unfortunately no published data exist on the use of 
traditional African medicine for menopausal symptoms.
11. No therapy for menopausal symptoms should be initiated 
without proper clinical assessment, including breast and pelvic 
examination.
It is concluded that every practitioner needs to be aware 
of the latest evidence on HT in order to assist patients in 
making informed decisions on menopausal management. It is 
anticipated that HT in conjunction with lifestyle modifications 
will remain the treatment of choice for acute menopausal 
symptoms in the immediate future. It is to be hoped that future 
research will be able to identify a patient profile or method of 
application where longer use of HT is without risk. This will 
unlock the true potential of HT in the prevention and treatment 
of osteoporosis and allow new research on the role of HT in 
primary prevention.
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